Prof. T.S. Ospanova, prof. Z.D. Semydotska, PHD. I.A. Chernyakova, PHD O.M. Pionova, PHD N.S. Tryfonova. Kharkiv National Medical University.

Department of Propedeutics of Internal Medicine No2 and nursing In the article is proposed to isolate the phenotype (subphenotype) of chronic obstructive pulmonary disease taking into account the functional state of the kidneys to minimize the risk of chronic kidney disease development.

Key Words: phenotype, chronic obstructive pulmonary disease, glomerular filtration rate, personified medicine.

Ospanova TS, Semydotska ZD, Chernyakova IA, Pionova OM, Tryfonova NS. [COPD phenotype — the way to personalized medicine ХХI century]. Shidnoevr. z. vnutr. simejnoi med. 2017;1:95-101. Russian.

https://dx.doi.org/10.15407/internalmed2017.01.095

Download.PDF

1. Feshhenko JuI, Chajkovs’kyj JuB, Ostrovs’kyj MM, Djel’cova OI, editors. Hronichne obstruktyvne zahvorjuvannja legen’: monografija. Ivano-Frankivs’k: SIMYK; 2016. 400 p. Ukrainian.

2. Feshchenko IuI. Khronicheskoe obstruktivnoe zabolevanie legkikh — aktual’naia mediko-sotsial’naia problema. Ukr.pul’monol. zhurnal. 2011;2:6 p. Russian.

3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006 Nov;3(11):e442. PubMed PMID: 17132052; PubMed Central PMCID: PMC1664601.

4. Avdeev SN, Baimakanova GE. KhOBL i serdechno-sosudistye zabolevaniia: mekhanizmy assotsiatsii. Pul’monologiia. 2008;1:5-13. Russian.

5. Klester EB. KhOBL v assotsiatsii s soputstvuiushchimi bolezniami sistemy krovoobrashcheniia, organov pishchevareniia, mochepolovoi sistemy. Osobennosti kliniki, techeniia, optimizatsiia kompleksnogo lecheniia. Barnaul; 2009. 46 p. Russian.

6. Trishina VV, Bychkova LV, Fedorenko MG. Rol’ KhOBL v razvitii pochechnoi patologii. Vestnik Rossiiskogo universiteta druzhby narodov. 2011;2:37-39. Russian.

7. Chuchalina AG. Khronicheskaia obstruktivnaia bolezn’ legkikh. Federal’naia programma. Moscow: RMZh; 2004. 61 p. Russian.

8. Chuchalin AG. Khronicheskaia obstruktivnaia bolezn’ legkikh i soputstvuiushchie zabolevaniia. Zdorov’e Ukrainy. 2010;2(231):26-27. Russian.

9. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J. 2006 Dec;28(6):1245-57. PMID: 17138679. DOI: 10.1183/09031936.00133805. https://doi.org/10.1183/09031936.00133805

10. Boev SS, Docenko NJa, Shehunova IA. Sochetanie HOBL i IBS. Voprosy racional’noj terapii. Ukraїns’kij medichnij vіsnik. 2005;2:95-96. Russian.

11. Kalmykov OO. Mehanizmy realizacii’ kardiorespiratornyh rozladiv za hronichnyh profesijnyh zahvorjuvan’ bronholegenevoi’ systemy iz suputn’oju ishemichnoju hvoroboju sercja: diagnostychni ta profilaktychni aspekty. Harkiv: NMU; 2016. 40 p. Ukrainian.

12. Fisher MB, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease – antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011;6:413-21. PMID: 21857781. PMCID: PMC3157944. DOI: 10.2147/COPD.S10770. https://doi.org/10.2147/COPD.S10770

13. Djel’cova OI, Genyk SM. Avtofagija-fundamental’ni mehanizmy i problemy. Svit medycyny ta biologii’. 2009;4:161-166. Ukrainian.

14. Boyer L, Savale L, Boczkowski J, Adnot S. Cellular senescence and pulmonare disease: COPD as an example. Rev Mal Respir. 2014 Dec;31(10):893-902. PMID: 25496787. DOI: 10.1016/j.rmr.2014.07.015. https://doi.org/10.1016/j.rmr.2014.07.015

15. Ryter SW, Choi AM. Autophagy in lung disease pathogenesis and therapeutics. Redox Biol. 2015;4:215-25. PMID: 25617802. PMCID: PMC4803789. DOI: 10.1016/j.redox.2014.12.010. https://doi.org/10.1016/j.redox.2014.12.010

16. Konopkina LI. Diagnostychna znachushhist’ dejakyh markeriv systemnogo zapalennja pry infekcijnomu zagostrenni hronichnogo obstruktyvnogo zahvorjuvannja legen’. Ukrai’ns’kyj pul’monologichnyj zhurnal. 2008;3:136-137. Ukrainian.

17. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med. 2014 Mar;35(1):131-41. PMID: 24507841. DOI: 10.1016/j.ccm.2013.09.006. https://doi.org/10.1016/j.ccm.2013.09.006

18. Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013 Dec;10 Suppl:S214-9. PMID: 24313775. DOI: 10.1513/AnnalsATS.201302-023AW. https://doi.org/10.1513/AnnalsATS.201302-023AW

19. Ambade VN, Sontakke AN, Barthwal MS. Diagnostic utility of biomarkers in COPD. Respir Care. 2015 Dec;60(12):1729-42. PMID: 26106205. DOI: 10.4187/respcare.03753. https://doi.org/10.4187/respcare.03753

20. Padygaeva AV. Fenotip KhOBL u zhenshchin s arterial’noi gipertenziei: osobennosti funktsional’nogo sostoianiia pochek. Kardiosomatika. 2015;2:40-46. Russian.

21. Han MK, Agusti A, Calverley PM. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010 Sep 1;182(5):598-604. PMID: 20522794. DOI: 10.1164/rccm.200912-1843CC. https://doi.org/10.1164/rccm.200912-1843CC

22. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet] Global Strategy for the Diagnosis, Management and Prevention of COPD, 2016. Available from: http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/

23. Pro zatverdzhennja klinichnyh protokoliv nadannja medychnoi’ dopomogy za special’nistju Pul’monologija: Nakaz Ministerstva oxoroni zdorovja Ukraini, 2007, No. №128 (Mar. 19, 2007. Ukrainian.

24. Unifikovanyj klinichnyj protokol pervynnoi’, vtorynnoi’ (specializovanoi’), tretynnoi’ (vysokospecializovanoi’) medychnoi’ dopomogy ta medychnoi’ reabilitacii’. Hronichne obstruktyvne zahvorjuvannja legeniv: Nakaz Ministerstva oxoroni zdorovja Ukraini, 2013, No. 555 (Jun. 27, 2013). Ukrainian.

25. Global Initiative for Chronic Obstructive Lung Disease (GOLD) [Internet] Global Strategy for the Diagnosis, Management and Prevention of COPD, 2017. Available from http:// http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/

26. Kadushkin AG, Taganovich AD. Molekuliarno-kletochnye mekhanizmy razvitiia khronicheskoi obstruktivnoi bolezni legkikh. Voennaia meditsina. 2012;1:132-138. Russian.

27. Krahmalova OO, Vojejkova L, Talalaj IV. Systemne zapalennja jak faktor rozvytku pozalegenevyh uskladnen’ HOZL. Ukrai’ns’kyj terapevtychnyj zhurnal. 2011;2:79-83. Ukrainian.

28. Ostrovs’kyj MM, Stovban MP. Fenotyp HOZL iz chastymy zagostrennjamy: vplyv na shvydkist’ progresuvannja hvoroby i prognoz dlja pacijenta. Zdorov’ja Ukrai’ny. 2013;19:29-30. Ukrainian.

29. Burgel PR. From COPD definition to COPD phenotypes. Presse Med. 2014;43(12 Pt1):1337-1343.

30. Vel’kov VV. Prokal’tsitonin i C-reaktivnyi belok v sovremennoi laboratornoi diagnostike. Laboratornaia diagnostika. 2010;2(52):39-76. Russian.

31. Toloh OS, Rudnyc’ka ND, Chulovs’ka UB, Vol’nyc’ka HI. Optymizacija terapii’ HOZL z urahuvannjam klinichnogo fenotypu. Klinichna imunologija. Alergologija. Infektologija. 2015;9-10(88-89):12-16. Ukrainian.

32. Barnes PJ. Identifying molecular targets for new drug development for chronic obstructive pulmonary disease: what does the future hold? Semin Respir Crit Care Med. 2015 Aug;36(4):508-22. PMID: 26238638. DOI: 10.1055/s-0035-1555611. https://doi.org/10.1055/s-0035-1555611

33. Lopez – Campos JL, Bustamante V, Munoz X. Moving towards patient-medicine for COPD management: multidimensional approaches versus phenotype-based medicine – a critical view. COPD. 2014 Sep;11(5):591-602. PMID: 24914771. DOI: 10.3109/15412555.2014.898035. https://doi.org/10.3109/15412555.2014.898035

34. Miyazaki M, Nakamura H, Takahashi S. The reasons for triple therapy in stable COPD patients in Japanese clinical practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:1053-1059.